-
Something wrong with this record ?
Steady survival improvements in soft tissue and bone sarcoma in the Nordic countries through 50 years
F. Tichanek, A. Försti, O. Hemminki, A. Hemminki, K. Hemminki
Language English Country Netherlands
Document type Journal Article
NLK
ProQuest Central
from 2009-07-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2009-07-01 to 2 months ago
Health & Medicine (ProQuest)
from 2009-07-01 to 2 months ago
Health Management Database (ProQuest)
from 2009-07-01 to 2 months ago
Public Health Database (ProQuest)
from 2009-07-01 to 2 months ago
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Young Adult MeSH
- Bone Neoplasms * mortality epidemiology pathology MeSH
- Soft Tissue Neoplasms mortality epidemiology pathology MeSH
- Osteosarcoma mortality epidemiology pathology therapy MeSH
- Registries MeSH
- Sarcoma * mortality epidemiology pathology therapy MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Finland MeSH
- Scandinavian and Nordic Countries MeSH
PURPOSE: Sarcomas are rare cancers with many subtypes in soft tissues, bone and cartilage. International survival trends in these cancers are not well known. We present 50-year survival trends for soft tissue sarcoma (STS) and bone sarcoma (BS) in Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE). METHODS: Relative 1-, 5/1 conditional- and 5-year survival data were obtained from the NORDCAN database for years 1971-20. We additionally estimated annual changes in survival rates and determined significant break points. RESULTS: In the last period, 2016-20, 5-year survival in STS was best for NO men (74.6%) and FI women (71.1%). For the rarer BS, survival rates for SE men (72.0%) and DK women (71.1%) were best. Survival in BS was lower than that in STS in 1971-75 and the difference remained in 2016-20 for men, but for women the rates were almost equal. Sex- and country-specific differences in survival in STS were small. The 50-year improvement in 5-year survival in STS was highest in NO men, 34.0 % units and FI women, 30.0 % units. The highest improvements in BS were in SE men 26.2 % units and in FI women 29.2 % units. CONCLUSIONS: The steady development in survival over the half century suggests contribution by stepwise improvements in diagnostics, treatment and care. The 10-15% mortality in the first year probably indicates diagnostic delays which could be improved by organizing patient pathways for aggressive rare diseases. Early diagnosis would also reduce metastatic disease and breakthroughs in treatment are a current challenge.
Biomedical Center Faculty of Medicine Charles University Pilsen 30605 Pilsen Czech Republic
Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Finland
Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland
Department of Urology Helsinki University Hospital Helsinki Finland
Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018833
- 003
- CZ-PrNML
- 005
- 20250819100802.0
- 007
- ta
- 008
- 241015e20230906ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.canep.2023.102449 $2 doi
- 035 __
- $a (PubMed)37679266
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Tichánek, Filip $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic; Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $7 xx0334827
- 245 10
- $a Steady survival improvements in soft tissue and bone sarcoma in the Nordic countries through 50 years / $c F. Tichanek, A. Försti, O. Hemminki, A. Hemminki, K. Hemminki
- 520 9_
- $a PURPOSE: Sarcomas are rare cancers with many subtypes in soft tissues, bone and cartilage. International survival trends in these cancers are not well known. We present 50-year survival trends for soft tissue sarcoma (STS) and bone sarcoma (BS) in Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE). METHODS: Relative 1-, 5/1 conditional- and 5-year survival data were obtained from the NORDCAN database for years 1971-20. We additionally estimated annual changes in survival rates and determined significant break points. RESULTS: In the last period, 2016-20, 5-year survival in STS was best for NO men (74.6%) and FI women (71.1%). For the rarer BS, survival rates for SE men (72.0%) and DK women (71.1%) were best. Survival in BS was lower than that in STS in 1971-75 and the difference remained in 2016-20 for men, but for women the rates were almost equal. Sex- and country-specific differences in survival in STS were small. The 50-year improvement in 5-year survival in STS was highest in NO men, 34.0 % units and FI women, 30.0 % units. The highest improvements in BS were in SE men 26.2 % units and in FI women 29.2 % units. CONCLUSIONS: The steady development in survival over the half century suggests contribution by stepwise improvements in diagnostics, treatment and care. The 10-15% mortality in the first year probably indicates diagnostic delays which could be improved by organizing patient pathways for aggressive rare diseases. Early diagnosis would also reduce metastatic disease and breakthroughs in treatment are a current challenge.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory kostí $x mortalita $x epidemiologie $x patologie $7 D001859
- 650 12
- $a sarkom $x mortalita $x epidemiologie $x patologie $x terapie $7 D012509
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory měkkých tkání $x mortalita $x epidemiologie $x patologie $7 D012983
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a osteosarkom $x mortalita $x epidemiologie $x patologie $x terapie $7 D012516
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a mladiství $7 D000293
- 651 _2
- $a Skandinávie a severské státy $x epidemiologie $7 D012537
- 651 _2
- $a Finsko $x epidemiologie $7 D005387
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
- 700 1_
- $a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland; Department of Urology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. Electronic address: k.hemminki@dkfz.de
- 773 0_
- $w MED00166636 $t Cancer epidemiology $x 1877-783X $g Roč. 92 (20230906), s. 102449
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37679266 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20250819100745 $b ABA008
- 999 __
- $a ok $b bmc $g 2201601 $s 1230806
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 92 $c - $d 102449 $e 20230906 $i 1877-783X $m Cancer epidemiology $n Cancer Epidemiol $x MED00166636
- LZP __
- $a Pubmed-20241015
